Analytical performance and clinical validity of two free prostate- specific antigen assays compared

Clinical Chemistry

Volumn 42, Issue 7, 1996, Pages 1026-1033

  Jung, Klaus ^a,b   Stephan, Carsten ^a   Lein, Michael ^a   Henke, Wolfgang ^a   Schnorr, Dietmar ^a   Brux, Brigitte ^a   Schürenkämper, Peter ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Luisenklinik   (Germany)

Author keywords

benign prostatic hyperplasia; method comparison study; prostate cancer; ROC analysis

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; GOOD LABORATORY PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC;

EID: 0029951253     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.7.1026     Document Type: Article

References (40)

1. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
2. 1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991;29:787-94.
3. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
4. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
5. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
6. Catalona WJ, Smith DS. Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer 1994;74:1516-8.
7. Prestigiacomo A, Stamey TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995;55(Suppl 221): 32-4.
8. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154: 1090-5.
9. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
10. Lilja H. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with cellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest 1995;55(Suppl 220): 47-56.
11. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application [Review]. Clin Chem 1993;39: 181-95.
12. Wu JT. Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal 1994;8:51-62.
13. Jung K, Lein M, Schnorr D, Henke W, Brux B, Loening SA. Prostataspezifisches Antigen (PSA). Einfluss des freien und gebundenen Anteils auf die klinische Aussagekraft als Tumor-marker. Lab Med 1995;19:210-7.
14. 1-antichymotrypsin complex. Clin Chem 1995; 41:1480-8.
15. Paus E, Fossa SD, Nilsson O, Eri M. The ratio of free to total PSA may be influenced by handling of serum samples [Abstract]. Anticancer Res 1995;15:2402.
16. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983;21:709-20.
17. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine [Review]. Clin Chem 1993;39:561-77.
18. Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 1995;55(Suppl222):43-60.
19. Blijenberg BG, Eman I, Boeve ER, Mössner E, Uhl W. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-test PSA assay for prostate-specific antigen. Eur J Clin Chem Clin Biochem 1995;33:383-92.
20. Wener MH, Daum PR, Brawer MK. Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin Chem 1995;41:1730-7.
21. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
22. Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994;102:531-7.
23. Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 1995;28:221-41.
24. Bjartell A, Björk T, Matikainen MT, Abrahamsson PA, di Sant'Agnese A, Lilja H. Production of alpha-1-antichymotrypsin by PSA-containing cells of the human prostate epithelium. Urology 1993;42:502-10.
25. Björk T, Hulkko S, Bjartell A, di Sant'Agnese A, Abrahamsson PA, Lilja H. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994;43:427-34.
26. Wu JT, Wilson L, Zhang P, Meikle AW, Stephenson R. Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 1995;9:15-24.
27. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H. Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-20.
28. Vessella RL, Noteboom J, Lange PH. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem 1992;38:2044-54.
29. Vessella RL. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity [Editorial]. Clin Chem 1993;39:2035-9.
30. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-91.
31. Stamey TA, Prestigiacomo AF, Chen Z. Standardization of immunoassays for prostate specfic antigen: a different view based on experimental observations. Cancer 1994;74:1662-6.
32. Belanger A, Vanhalbeek H, Graves HCB, Grandbois K, Stamey TA, Huang LH, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995;27:187-97.
33. 1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin Chem 1995;41:1273-82.
34. Sokoloff RL, Wolfert RL, Rittenhouse HG. Standardization of PSA immunoassays: proposals and practical limitations. J Clin Ligand Assay 1995;18:86-92.
35. 1-antichymotrypsin (PSA/ ACT) and uncomplexed PSA in serum from patients with benign prostate hypertrophy (BPH) and prostate cancer (PCA) using dual monoclonal assays [Abstract]. J Urol 1993;149(Suppl):333A.
36. Wilson L, Stephenson R, Meikle W, Wu J. Measurement of serum PSA-ACT complex in patients with BPH and prostate cancer: feasibility and advantages [Abstract]. Clin Chem 1994;40:1004.
37. 1-antichymotrypsin. Prostate 1995;27:166-75.
38. Stamey TA, Chen Z, Prestigiacomo A. Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994;152:1510-4.
39. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2037-42.
40. Jacobsen SJ, Oesterling JE. Age-specific reference ranges for serum prostate specific antigen levels. J Clin Ligand Assay 1995;18:93-7.